Company profile: Unicycive Therapeutics
1.1 - Company Overview
Company description
- Provider of kidney disease therapeutics development programs addressing unmet medical needs, including UNI-494, a patented pro-drug of nicorandil in development for acute kidney injury to improve mitochondrial function, and Oxylanthanum Carbonate, an investigational drug under FDA’s 505(b)(2) for hyperphosphatemia using nanoparticle technology to potentially reduce pill burden.
Products and services
- Development Programs: Architects indication-focused development programs targeting kidney diseases with unmet medical needs, concentrating on therapies to treat renal conditions where effective options are limited
- Oxylanthanum Carbonate (OLC): Engineers an investigational, nanoparticle-based drug under FDA’s 505(b)(2) pathway for hyperphosphatemia, designed to potentially reduce pill burden while treating elevated phosphate levels
- UNI-494: Builds a patented pro-drug of nicorandil for acute kidney injury (AKI), aiming to improve mitochondrial function to support renal recovery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Unicycive Therapeutics
USGI Medical
HQ: United States
Website
- Description: Provider of incisionless surgical technologies for gastrointestinal procedures, offering the Incisionless Operating Platform to address GI procedural challenges; the POSE2.0 endoscopic gastroplasty using Snowshoe Suture Anchors to provide gastric restriction without removing part of the stomach; and tools including the g-Cath Tissue Anchor Delivery Catheter, g-Prox EZ Endoscopic Grasper, and Transport Endoscopic Guide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full USGI Medical company profile →
HepaRegeniX
HQ: Germany
Website
- Description: Provider of drug candidates targeting MKK4 to restore hepatocyte regeneration for acute and chronic liver diseases. Pipeline includes HRX-0215, a first-in-class MKK4 inhibitor in clinical trials, and HRX-0233, a second MKK4 inhibitor under preclinical collaborations for cancer combination therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HepaRegeniX company profile →
Keryx Biopharmaceuticals
HQ: United States
Website
- Description: Provider of innovative biopharmaceutical medicines, focused on their development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keryx Biopharmaceuticals company profile →
Genfit
HQ: France
Website
- Description: Provider of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, dedicated to discovery and development in areas with considerable unmet medical needs where approved treatments are lacking; a late-stage biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genfit company profile →
Theratechnologies
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies, including Trogarzo for HIV in individuals with limited treatment options due to resistance, intolerance, or safety considerations; EGRIFTA SV (tesamorelin) to reduce excess abdominal fat in HIV patients with lipodystrophy; and Long Acting Peptides and the SORT1+ oncology platform. Pipeline includes tesamorelin for NASH, F8 bioequivalent formulation, and a multi-dose pen injector in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theratechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Unicycive Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Unicycive Therapeutics
2.2 - Growth funds investing in similar companies to Unicycive Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Unicycive Therapeutics
4.2 - Public trading comparable groups for Unicycive Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →